Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Qiagen ( (QGEN) ) is now available.
The Netherlands Authority for the Financial Markets (AFM) has notified QIAGEN N.V. about a voting rights announcement involving Barclays Plc, which was disclosed on the AFM website. The notification details various shareholdings and voting rights held indirectly by Barclays through its subsidiaries, indicating a capital interest and voting rights of 2.93% in QIAGEN. This announcement highlights the significant involvement of Barclays in QIAGEN’s shareholding structure, potentially impacting the company’s governance and stakeholder relations.
The most recent analyst rating on (QGEN) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, specializing in molecular diagnostics and sample preparation technologies. The company is known for providing solutions that enable customers to gain valuable insights from biological samples, with a market focus on healthcare and research sectors.
Average Trading Volume: 1,445,625
Technical Sentiment Signal: Buy
Current Market Cap: $9.97B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.